An interventional study of TXA administration and Placebo administration in Heart Diseases, Vascular Diseases and Transfusion Related Complication, sponsored by Konkuk University Medical Center. Completed at 3 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Konkuk University Medical Center · Not applicable, Interventional, and Diagnostic
Among 31 studies in Heart Diseases with a site in Korea, Republic of — 8 open to participants now, 10 under way, 2 of them phase 3. Heart Diseases · Korea, Republic of.
Among the 31 studies in Heart Diseases with a site in Korea, Republic of, this one is the 11th largest by enrollment of the 23 interventional ones that give a count, is one of 4 that started in 2023, is one of 12 with no phase, and was the 23rd registered.
2,135 studies on the registry are indexed under Heart Diseases; 252 are open to participants now.
Browse Heart Diseases studies →8 of the 31 studies in Heart Diseases with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Korea, Republic of, Argentina, Australia and 35 more countries
Ages 50+
Eidos Therapeutics, a BridgeBio company · Sites in Korea, Republic of, United States, Argentina and 21 more countries
Ages 18–75
Weill Medical College of Cornell University · Sites in Korea, Republic of, United States, Australia and 23 more countries
Ages 18+ · Women only
Kangbuk Samsung Hospital · Sites in Korea, Republic of
Ages 18+
Jung-min Ahn · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 181 Heart Diseases studies recruiting now, 128 (71%) set no upper age limit and 21 (12%) stop at 75 or younger; 32 take children under 18; 42 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 764 is above the median of 129 across 931 interventional studies indexed under Heart Diseases.
Median enrollment 632 across the 23 interventional studies, 1,100 across the 8 observational. Of the 19 that completed or were terminated, 8 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 31 have an industry lead sponsor. The 10 most frequent:
Konkuk University Medical Center is the lead sponsor of 95 studies on the registry; 15 are open to participants now.
Konkuk University Medical Center has 2 studies filed under Heart Diseases — fewer than ten, so there is no comparison to draw.
2 of the studies in Heart Diseases with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05044273Jung-min AhnEvaluation of Effectiveness and Safety of Synergy XD and Synergy Megatron™ Stent | 2026-12-31 |
| NCT05846893B. Braun Medical Industries Sdn. Bhd.Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 31 studies in Heart Diseases with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The present study is a multi-center randomized prospective placebo-controlled non-inferiority trial.
The study's primary objective is to compare the amounts of postoperative bleeding using two different TXA administration strategies: empirical TXA administration vs. viscoelastic test-based goal-directed TXA administration in cardiovascular surgery.
The secondary objectives include comparing the incidents of hyper-fibrinolysis, thromboembolic complications, and postoperative seizures.
Researchers assumed that goal-directed tranexamic acid (TXA) administration using viscoelastic field tests would not be inferior to the empirical TXA administration strategy in reducing postoperative bleeding and hyper-fibrinolysis. It also would be beneficial in lowering TXA-induced thromboembolic complications and seizures.
The present study is a multi-center randomized prospective placebo-controlled non-inferiority trial.
This study's primary objective is to compare the amounts of postoperative bleeding during postoperative 24 hours through chest tube drainage using two different tranexamic acid (TXA) administration strategies: empirical TXA administration vs. viscoelastic test-based goal-directed TXA administration in cardiovascular surgery.
The secondary objectives include determining the inter-group differences in hyper-fibrinolysis, thromboembolic complications, and postoperative seizures.
Researchers hypothesized that goal-directed TXA administration using viscoelastic field tests would not be inferior to the empirical TXA administration strategy in reducing postoperative bleeding and hyper-fibrinolysis. Researchers also expect that goal-directed TXA administration would be beneficial in lowering TXA-induced thromboembolic complications and seizure risks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tranexamic acid administration, regardless of the result of rotational thromboelastometry. Placebo administration, at LI60 \< 85 % or A10\< 40 mm in EXTEM of rotational thromboelastometry
Drug: TXA administration · Drug: Placebo administration
Tranexamic acid administration, regardless of the result of rotational thromboelastometry. Placebo discard, at LI60 ≥ 85% or A10 ≥ 40 mm in EXTEM of rotational thromboelastometry
Drug: TXA administration
Placebo administration, regardless of the result of rotational thromboelastometry. Tranexamic acid administration at LI60 \< 85 % or A10 \< 40 mm in EXTEM of rotational thromboelastometry
Drug: TXA administration · Drug: Placebo administration
Placebo administration, regardless of the result of rotational thromboelastometry. Tranexamic acid discard at LI60 ≥ 85% or A10 ≥ 40 mm in EXTEM of rotational thromboelastometry
Drug: Placebo administration
Tranexamic acid intravenous administration
Also known as: Tranexamic acid
Placebo (normal saline) intravenous administration
Also known as: Placebo (normal saline)
postoperative bleeding
bleeding amount though chest drainage tubes during the 1st postoperative 24 hour
Time frame: 24 hours
postoperative transfusion amount
amounts of transfused red blood cells, plasma, platelet and cryoprecipitate
Time frame: 24 hours
postoperative transfusion rate
incidents of red blood cells, plasma, platelet and cryoprecipitate transfusions
Time frame: 24 hours
the lowest postoperative hemoglobin value
the nadir hemoglobin value during one postoperative days
Time frame: 24 hours
incidence of reoperation
incidence of reoperation due to postoperative bleeding
Time frame: 1 week
amount of intraoperative cell salvage
amounts of infused salvaged blood
Time frame: 1 hour
viscoelastic whole blood profile
values of intraoperative CT-EXTEM, CFT-EXTEM, A10-EXTEM, MCF-EXTEM, ML-EXTEM, LY30-EXTEM, CT-FIBTEM, CFT-FIBTEM, A10-FIBTEM, MCF-FIBTEM, ML-FIBTEM in rotational thromboelastometry
Time frame: 1 hour
incidence of seizure
incidence of postoperative seizure till the hospital discharge
Time frame: 1 week
incidence of thromboembolic complications
incidence of postoperative myocardia infarction, stroke, pulmonary embolism, gut infarction till the hospital discharge
Time frame: 1 week
duration of mechanical ventilation
duration of postoperative ventilatory care
Time frame: 1 week
length of stays in the ICU and hospital
duration of stay in the ICU and hospital
Time frame: 1 week
total cost
total expense paid at the discharge
Time frame: 2 week
incidence of taking renal replacement therapy
incidence of taking hemodylaysis
Time frame: 1 week
incidence of acute kidney injury
diagnosed by KIDGO criteria
Time frame: 1 week
incidence of postoperative delirium
delirium digested by CAM-ICU
Time frame: 1 week
incidence of applying for mechanical circulatory support
incidences of applying IABP, ECMO, VAD
Time frame: 1 week
in-hospital mortality
hospital death
Time frame: 1 week
central laboratory blood tests
hemoglobin, platelet number, Prothrombin timeI activated partial thromboplastin timePTT , fibrinogen concentration, d-dimer
Time frame: 1 week
Days alive at home
Counts days spent living at home during the first 30 and 90 postoperative days
Time frame: 1 month
Fibrinolysis phenotype
Hyperfibrinolysis, physiologic fibrinolysis, fibrinolysis shutdown
Time frame: 1 hour
Plan to share: No
Ran from Aug 2023 to primary completion in Oct 2026, 38 months.
Of 263 non-industry interventional studies with no phase under Heart Diseases, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's 38 months is above that.
Counting every sponsor, half of 336 studies reached it within 25 months; a quarter within 10 and three quarters within 52.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Apr 2025 → Oct 2026 and completion Jun 2025 → Oct 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tranexamic Acid
Konkuk University Medical Center